| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J Thorac Cardiovasc Surg 2002;123:715-723
© 2002 The American Association for Thoracic Surgery
Surgery for Acquired Cardiovascular Disease (ACD) |
From the Department of Cardiothoracic Surgery,a University Hospital of Wales, Cardiff, United Kingdom, and the Medical Data Research Centre,b Providence Health System, Portland, Ore.
Funding for this study was provided by Medtronic, Inc, Minneapolis, Minn.
Received for publication June 28, 2001. Accepted for publication Sept 26, 2001. Address for reprints: Eric G. Butchart, FRCS, FESC, Department of Cardiothoracic Surgery, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, United Kingdom (E-mail: egbutchart{at}aol.com).
Objective: We sought to assess the effect of anticoagulation control on long-term survival after valve replacement with the Medtronic Hall valve (Medtronic, Inc, Minneapolis, Minn).
Methods: Prospective follow-up data, including 82,297 international normalized ratios, were collected for 1476 patients undergoing single valve replacement with the Medtronic Hall valve between 1979 and 1994, with follow-up to the end of 1998. After excluding 204 patients who either died within 30 days or had fewer than 10 international normalized ratios recorded beyond 30 days, there were 10,203 patient years of follow-up for analysis. Anticoagulation variability was measured as the percentage of international normalized ratios outside a target range of 2.0 to 4.0 for each patient.
Results: Linearized rates for late death rose progressively with increasing deciles of anticoagulation variability for both aortic and mitral valve replacement (2.7% and 3.3% per year, respectively, in deciles 1 and 2 up to 9.5% and 14.6% per year, respectively, in deciles 6-10; P < .001). Survival at 15 years after aortic valve replacement was 59% for low anticoagulation variability (deciles 1 and 2), 55% for intermediate anticoagulation variability (decile 3), and 28% for high anticoagulation variability (deciles 4-10); survivals at 15 years after mitral valve replacement were 56%, 42%, and 24%, respectively (P < .001 between low-intermediate anticoagulation variability and high anticoagulation variability for both aortic and mitral valve replacement). On multivariate analysis, significant predictors of reduced survival were anticoagulation variability per 20% increase (hazard ratio, 1.8), diabetes (hazard ratio, 1.6), decade of age (hazard ratio, 1.6), concomitant coronary artery bypass grafting (hazard ratio, 1.5), male sex (hazard ratio, 1.4), hypertension (hazard ratio, 1.4), New York Heart Association class III or IV (hazard ratio, 1.3), and non-sinus rhythm (hazard ratio, 1.2). Patients with low anticoagulation variability who were in sinus rhythm and did not have diabetes, coronary bypass grafting, or hypertension had survivals equal to those of the age- and sex-matched general population at 15 years. The incidence of valve-related deaths was significantly higher with high anticoagulation variability compared with the incidence with low-intermediate anticoagulation variability for both aortic (1.4% vs 0.5% per year, P < .001) and mitral valve replacement (1.5% vs 0.5% per year, P < .001). By means of univariate analysis, high anticoagulation variability was significantly associated with New York Heart Association class III or IV at 5 years postoperatively (P < .001) and with age of greater than 60 years at the time of the operation (P = .002).
Conclusions: High anticoagulation variability is the most important independent predictor of reduced survival after valve replacement with a mechanical valve. Better anticoagulation control should improve survival.
This article has been cited by other articles:
|
|
 |
|
  K. Shaikhrezai, G. Tasca, M. Amrani, G. Dreyfus, and G. Asimakopoulos Third-Time Aortic Valve Replacement: Patient Characteristics and Operative Outcome. Ann. Thorac. Surg., February 1, 2010; 89(2): 479 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Houston, R. Zarychanski, H. Tomoda, M. Moia, P. M. Mannucci, J. M. Worthington, M. Gattellari, L. Poller, J. Jespersen, S. Ibrahim, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., December 31, 2009; 361(27): 2671 - 2672. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Le Tourneau, V. Lim, J. Inamo, F. A. Miller, D. W. Mahoney, H. V. Schaff, and M. Enriquez-Sarano Achieved Anticoagulation vs Prosthesis Selection for Mitral Mechanical Valve Replacement: A Population-Based Outcome Study Chest, December 1, 2009; 136(6): 1503 - 1513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. G Butchart Antithrombotic management in patients with prosthetic valves: a comparison of American and European guidelines Heart, March 1, 2009; 95(5): 430 - 436. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pibarot and J. G. Dumesnil Prosthetic Heart Valves: Selection of the Optimal Prosthesis and Long-Term Management Circulation, February 24, 2009; 119(7): 1034 - 1048. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vahanian, B. Iung, L. Piérard, R. Dion, and J. Pepper CHAPTER 21 Valvular Heart Disease ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, and G. Palareti Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 160S - 198S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Eitz, S. Schenk, D. Fritzsche, A. Bairaktaris, O. Wagner, H. Koertke, and R. Koerfer International Normalized Ratio Self-Management Lowers the Risk of Thromboembolic Events After Prosthetic Heart Valve Replacement Ann. Thorac. Surg., March 1, 2008; 85(3): 949 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Emery, A. M. Emery, A. Knutsen, and G. V. Raikar Aortic Valve Replacement with a Mechanical Cardiac Valve Prosthesis Card. Surg. Adult, January 1, 2008; 3(2008): 841 - 856. [Full Text]
|
|
|
|
|
|
M. Vicchio, A. Della Corte, M. De Feo, G. Santarpino, L. S. De Santo, G. Romano, G. Caianiello, M. Scardone, and M. Cotrufo Quality of Life After Implantation of Bileaflet Prostheses in Elderly Patients: An Anticoagulation Work Group Experience Ann. Thorac. Surg., August 1, 2007; 84(2): 459 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bayliss, P. Faber, J. Dunning, and A. Ronald What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve? Interactive CardioVascular and Thoracic Surgery, June 1, 2007; 6(3): 390 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Oake, D. A. Fergusson, A. J. Forster, and C. van Walraven Frequency of adverse events in patients with poor anticoagulation: a meta-analysis Can. Med. Assoc. J., May 22, 2007; 176(11): 1589 - 1594. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, A. Vahanian, H. Baumgartner, J. Bax, E. Butchart, R. Dion, G. Filippatos, F. Flachskampf, R. Hall, B. Iung, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology Eur. Heart J., January 26, 2007; (2007) ehl428v1. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rahman, T. M BinEsmael, N. Payne, and E. G Butchart Increased Sensitivity to Warfarin After Heart Valve Replacement Ann. Pharmacother., March 1, 2006; 40(3): 397 - 401. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. G. Butchart, C. Gohlke-Barwolf, M. J. Antunes, P. Tornos, R. De Caterina, B. Cormier, B. Prendergast, B. Iung, H. Bjornstad, C. Leport, et al. Recommendations for the management of patients after heart valve surgery Eur. Heart J., November 2, 2005; 26(22): 2463 - 2471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Tominaga, K. Kurisu, Y. Ochiai, Y. Tomita, M. Masuda, S. Morita, and H. Yasui A 10-Year Experience With the Carbomedics Cardiac Prosthesis Ann. Thorac. Surg., March 1, 2005; 79(3): 784 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. G. Butchart and C. Gohlke-Barwolf Anticoagulation management of patients with prosthetic valves J. Am. Coll. Cardiol., September 1, 2004; 44(5): 1143 - 1144. [Full Text] [PDF]
|
|
|
|
|
|
R. Vink, R. A. Kraaijenhagen, B. A. Hutten, R. B. A. van den Brink, B. A. de Mol, H. R. Buller, and M. Levi The optimal intensity of vitamin k antagonists in patients with mechanical heart valves: A meta-analysis J. Am. Coll. Cardiol., December 17, 2003; 42(12): 2042 - 2048. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H. Blackstone, D. M. Cosgrove, W.R. E. Jamieson, N. J. Birkmeyer, J. H. Lemmer Jr, D. C. Miller, E. G. Butchart, G. Rizzoli, M. Yacoub, and A. Chai Prosthesis size and long-term survival after aortic valve replacement J. Thorac. Cardiovasc. Surg., September 1, 2003; 126(3): 783 - 793. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
